REWIND, DECLARE, and high-risk diabetes patients | diabetes.medicinematters.com

Medicine Matters Diabetes

Top

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

LISTEN: How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti (9:04).

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video

Medicine Matters Diabetes

REWIND, DECLARE, and high-risk diabetes patients

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Related content

Dulaglutide cardioprotective in relatively low-risk REWIND population

Expert commentary: A nurse educator’s view of the REWIND trial

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Round-up of the DPP-4 inhibitor CV outcome trials

Medicine Matters Diabetes

External Content

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Related content

Dulaglutide cardioprotective in relatively low-risk REWIND population

Expert commentary: A nurse educator’s view of the REWIND trial

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Round-up of the DPP-4 inhibitor CV outcome trials